| Matrix metalloproteinase inhibitors: new challenges in the era of post broad-spectrum inhibitors E Nuti, T Tuccinardi, A Rossello Current pharmaceutical design 13 (20), 2087-2100, 2007 | 140 | 2007 |
| Combining the tail and the ring approaches for obtaining potent and isoform-selective carbonic anhydrase inhibitors: solution and X-ray crystallographic studies M Bozdag, M Ferraroni, E Nuti, D Vullo, A Rossello, F Carta, A Scozzafava, ... Bioorganic & Medicinal Chemistry 22 (1), 334-340, 2014 | 116 | 2014 |
| New N-arylsulfonyl-N-alkoxyaminoacetohydroxamic acids as selective inhibitors of gelatinase A (MMP-2) A Rossello, E Nuti, E Orlandini, P Carelli, S Rapposelli, M Macchia, ... Bioorganic & medicinal chemistry 12 (9), 2441-2450, 2004 | 103 | 2004 |
| Amber force field implementation, molecular modelling study, synthesis and MMP-1/MMP-2 inhibition profile of (R)-and (S)-N-hydroxy-2-(N-isopropoxybiphenyl-4-ylsulfonamido)-3 … T Tuccinardi, A Martinelli, E Nuti, P Carelli, F Balzano, G Uccello-Barretta, ... Bioorganic & medicinal chemistry 14 (12), 4260-4276, 2006 | 99 | 2006 |
| Strategies to target ADAM17 in disease: from its discovery to the iRhom revolution M Calligaris, D Cuffaro, S Bonelli, DP Spanò, A Rossello, E Nuti, ... Molecules 26 (4), 944, 2021 | 89 | 2021 |
| Vascular ADAM17 as a novel therapeutic target in mediating cardiovascular hypertrophy and perivascular fibrosis induced by angiotensin II T Takayanagi, SJ Forrester, T Kawai, T Obama, T Tsuji, KJ Elliott, E Nuti, ... Hypertension 68 (4), 949-955, 2016 | 84 | 2016 |
| N-O-Isopropyl Sulfonamido-Based Hydroxamates: Design, Synthesis and Biological Evaluation of Selective Matrix Metalloproteinase-13 Inhibitors as Potential … E Nuti, F Casalini, SI Avramova, S Santamaria, G Cercignani, L Marinelli, ... Journal of medicinal chemistry 52 (15), 4757-4773, 2009 | 81 | 2009 |
| Inhibition of metalloproteinases derived from tumours: new insights in the treatment of human glioblastoma P Gabelloni, E Da Pozzo, S Bendinelli, B Costa, E Nuti, F Casalini, ... Neuroscience 168 (2), 514-522, 2010 | 75 | 2010 |
| N-O-Isopropyl Sulfonamido-Based Hydroxamates as Matrix Metalloproteinase Inhibitors: Hit Selection and in Vivo Antiangiogenic Activity E Nuti, AR Cantelmo, C Gallo, A Bruno, B Bassani, C Camodeca, ... Journal of Medicinal Chemistry 58 (18), 7224-7240, 2015 | 73 | 2015 |
| Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhibitors E Nuti, L Panelli, F Casalini, SI Avramova, E Orlandini, S Santamaria, ... Journal of medicinal chemistry 52 (20), 6347-6361, 2009 | 69 | 2009 |
| Crystallization of bi-functional ligand protein complexes C Antoni, L Vera, L Devel, MP Catalani, B Czarny, E Cassar-Lajeunesse, ... Journal of Structural Biology 182 (3), 246-254, 2013 | 63 | 2013 |
| Dual inhibitors of matrix metalloproteinases and carbonic anhydrases: iminodiacetyl-based hydroxamate− benzenesulfonamide conjugates SM Marques, E Nuti, A Rossello, CT Supuran, T Tuccinardi, A Martinelli, ... Journal of medicinal chemistry 51 (24), 7968-7979, 2008 | 63 | 2008 |
| α-Biphenylsulfonylamino 2-methylpropyl phosphonates: Enantioselective synthesis and selective inhibition of MMPs A Biasone, P Tortorella, C Campestre, M Agamennone, S Preziuso, ... Bioorganic & medicinal chemistry 15 (2), 791-799, 2007 | 62 | 2007 |
| Structural insights on carbonic anhydrase inhibitory action, isoform selectivity, and potency of sulfonamides and coumarins incorporating arylsulfonylureido groups M Bozdag, M Ferraroni, F Carta, D Vullo, L Lucarini, E Orlandini, ... Journal of Medicinal Chemistry 57 (21), 9152-9167, 2014 | 61 | 2014 |
| Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with sulfonylated hydroxamates E Nuti, E Orlandini, S Nencetti, A Rossello, A Innocenti, A Scozzafava, ... Bioorganic & medicinal chemistry 15 (6), 2298-2311, 2007 | 60 | 2007 |
| Discovery of a new selective inhibitor of A Disintegrin And Metalloprotease 10 (ADAM-10) able to reduce the shedding of NKG2D ligands in Hodgkin's lymphoma cell models C Camodeca, E Nuti, L Tepshi, S Boero, T Tuccinardi, EA Stura, A Poggi, ... European Journal of Medicinal Chemistry 111, 193-201, 2016 | 55 | 2016 |
| Ni-Propoxy-N-biphenylsulfonylaminobutylhydroxamic acids as potent and selective inhibitors of MMP-2 and MT1-MMP A Rossello, E Nuti, P Carelli, E Orlandini, M Macchia, S Nencetti, ... Bioorganic & medicinal chemistry letters 15 (5), 1321-1326, 2005 | 54 | 2005 |
| ADAM10 new selective inhibitors reduce NKG2D ligand release sensitizing Hodgkin lymphoma cells to NKG2D-mediated killing MR Zocchi, C Camodeca, E Nuti, A Rossello, R Venè, F Tosetti, I Dapino, ... Oncoimmunology 5 (5), e1123367, 2016 | 49 | 2016 |
| Targeting ADAM17 sheddase activity in cancer A Rossello, E Nuti, S Ferrini, M Fabbi Current drug targets 17 (16), 1908-1927, 2016 | 47 | 2016 |
| Potent arylsulfonamide inhibitors of tumor necrosis factor-α converting enzyme able to reduce activated leukocyte cell adhesion molecule shedding in cancer cell models E Nuti, F Casalini, SI Avramova, S Santamaria, M Fabbi, S Ferrini, ... Journal of medicinal chemistry 53 (6), 2622-2635, 2010 | 47 | 2010 |
